TL;DR
Existing equations for estimating Glomerular Filtration Rate (GFR) from serum creatinine are inaccurate for the Indian population due to differences in body composition and diet. This study aims to develop and validate a new, more accurate creatinine-based GFR estimation equation specifically for Indians, which will improve the diagnosis, classification, and management of Chronic Kidney Disease (CKD).
What Problem Does This Paper Address?
Estimating Glomerular Filtration Rate (GFR) is crucial for diagnosing and managing Chronic Kidney Disease (CKD). The most common method for estimating GFR (eGFR) relies on serum creatinine levels. However, widely used eGFR equations, such as CKD-EPI and MDRD, were primarily developed and validated in populations of European and African American ancestry. These equations have shown suboptimal accuracy when applied to the Indian population. This inaccuracy is attributed to significant differences in body composition (e.g., shorter stature, less muscle mass, higher prevalence of central obesity), dietary habits (predominantly vegetarian), and other factors that influence serum creatinine levels independently of GFR. Consequently, these existing equations may lead to misdiagnosis, delayed treatment, or inappropriate management of CKD in India, where a substantial portion of the global population resides. This study addresses this critical gap by proposing the development of a region-specific eGFR equation for the Indian population.
Methods
This study employs a cross-sectional design with a multi-stage sampling approach across two geographically and demographically diverse locations in India: Chandigarh (North) and Puducherry (South).
The core methodology involves:
- Measured GFR (mGFR) as the Reference Standard: The study utilizes plasma clearance of iohexol as the reference standard for measuring GFR. Iohexol is a nonionic contrast agent chosen for its favorable properties, including low protein binding and minimal extra-renal elimination, making it a convenient and accurate alternative to traditional methods.
- Iohexol Measurement: Iohexol will be administered intravenously, and blood samples will be collected at multiple time points (0, 60, 120, 180, and 240 minutes) for plasma clearance analysis. The study also explores the feasibility of using dried blood spots (DBS) for iohexol measurement, a minimally invasive technique that could facilitate large-scale studies.
- Equation Development: A stepwise multiple regression analysis on log-transformed data will be used to identify variables that jointly predict mGFR. The prediction equation will be a multiplicative model. Potential predictors include age, sex, weight, height, North/South Indian origin, and serum creatinine. Other factors like waist circumference, body fat, muscle mass, serum albumin, and fasting blood glucose will also be explored.
- Correction Factor for CKD-EPI: In addition to developing a new equation, the study will also develop a correction factor for the existing CKD-EPI equation to improve its performance in the Indian population. This will involve a linear regression model using log-transformed mGFR and log-transformed CKD-EPI eGFR.
- Performance Evaluation: The performance of the developed equations will be assessed using metrics such as bias, precision (interquartile range of differences), root mean square error (RMSE), and accuracy (P30 - percentage of estimates within 30% of mGFR). Cross-validation and external validation will be performed using separate datasets.
- DBS Validation: The study will assess the bias, precision, and accuracy of mGFR estimated from DBS iohexol clearance against venous blood plasma iohexol clearance.
Datasets
The study will utilize data collected from participants enrolled in Chandigarh and Puducherry.
- Discovery and Cross-validation Cohort: A total of 1558 subjects will be enrolled for the derivation and cross-validation of the eGFR equation. This cohort will include a representative sample from the general population and subjects with CKD recruited from outpatient clinics.
- External Validation Cohort: A separate set of 620 subjects from the general population and CKD patients will be used for external validation.
- Additional Validation Data: The study also plans to use data from another general population cohort (120 subjects) and 500 subjects from the ICKD study for external validation.
No pre-existing public datasets are mentioned as being used for training or evaluation. The study aims to generate its own dataset for this specific purpose.
Key Insights and Ideas
- The "Indian Factor" in GFR Estimation: The fundamental insight is that existing eGFR equations, developed in Western populations, are not universally applicable and fail to capture the unique physiological characteristics of the Indian population. This highlights the importance of developing region-specific equations for accurate clinical assessment.
- Iohexol as a Practical Gold Standard: The study's reliance on iohexol clearance as the reference standard, rather than traditional but more complex methods like inulin clearance, demonstrates a practical approach to obtaining accurate GFR measurements in a research setting.
- The Promise of Dried Blood Spots (DBS): Exploring DBS for iohexol measurement is a significant step towards making accurate GFR assessment more accessible. DBS technology offers advantages in terms of ease of collection, storage, and transport, potentially enabling large-scale epidemiological studies and wider clinical application.
- Beyond Creatinine: Exploring Other Determinants: The study's intention to investigate factors beyond serum creatinine that influence GFR (e.g., body composition, dietary protein intake) and factors that non-GFR-dependently affect serum creatinine is crucial for a comprehensive understanding of kidney function in the Indian context.
Key Results
As this paper focuses on the design and methods, specific quantitative results regarding the accuracy of the developed equation are not yet available. However, the study outlines the rigorous approach to achieve these results:
- Sample Size: A substantial sample size of 1558 for derivation/cross-validation and 620 for external validation is planned to ensure robust statistical power.
- Performance Metrics: The study will report bias, precision, RMSE, and P30 (accuracy within 30% of mGFR) for the new equation.
- Agreement Metrics: For DBS validation, concordance correlation coefficient (CCC), total deviation index (TDI), and coverage probability (cp) will be used.
- Statistical Significance: A P-value <0.01 will be used for variable entry in the regression model for equation derivation, and P <0.05 for correction factor development.
Limitations and Future Work
- Geographic Representation: The study acknowledges that including participants from only two states (North and South India) may not fully represent the entire Indian population, which is highly diverse.
- Cross-sectional Design: The cross-sectional nature of the study means it can determine GFR ranges and associations but cannot establish the physiological significance of low GFR values over time or their impact on outcomes.
- Future Work: The authors suggest that future work should involve following up the population to determine the influence of low GFR values on outcomes. The successful validation of DBS sampling could pave the way for its use in large-scale epidemiological studies. The development of a validated, accurate eGFR equation for the Indian population is expected to have substantial implications for CKD research and clinical practice in India and similar regions.
Summary updated